JCEM:PTH用于甲状腺癌术后低钙血症的预防作用

2021-09-10 从医路漫漫 MedSci原创

评价特立帕肽是否能预防甲状腺术后低钙血症高危患者术后低钙血症的发生率并缩短患者的住院时间。

背景:尚无研究评价特立帕肽预防甲状腺切除术后低钙血症的研究。 目的:评价特立帕肽是否能预防甲状腺术后低钙血症高危患者术后低钙血症的发生率并缩短患者的住院时间。 设计:前瞻性II期随机开放试验。患者:26例(男6例,女20例)iPTH<10 pg/ml,甲状腺切除术后4小时。干预:受试者被随机分组(1:1),治疗组每12小时皮下注射20ug特立帕肽直到出院,对照组遵循标准临床护理。主要观察指标:调整后的血清钙、住院时间、补充钙剂或骨化三醇。 结果:治疗组低钙血症发生率为3/13,对照组低钙血症发生率为11/13 (P=0.006)。接受治疗的患者发生低钙血症的风险低于对照组[RR 0.26 (95% CI:0.09 - 0.723)]。对照组患者中位住院时间为3天(IQR:1),治疗组患者中位住院时间为2天(IQR:0) (P?0.012)。出院1个月后,治疗组10/13的受试者停止补充碳酸钙,而对照组只有5/13的受试者补充钙。ANOVA方差分析显示,两组患者在治疗1个月时的钙补充量有显著差异(P=0.04),治疗组出院和治疗1个月时的钙补充量也有显著差异(P = 0.04)。 图1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063500, encodeId=97e3206350068, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 11 07:15:31 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778118, encodeId=b99b1e7811820, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 10 08:15:31 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024130, encodeId=6be120241307a, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue May 17 19:15:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999124, encodeId=b3f019991248e, content=<a href='/topic/show?id=215c26381aa' target=_blank style='color:#2F92EE;'>#低钙血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26381, encryptionId=215c26381aa, topicName=低钙血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Thu May 05 09:15:31 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-08-11 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063500, encodeId=97e3206350068, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 11 07:15:31 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778118, encodeId=b99b1e7811820, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 10 08:15:31 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024130, encodeId=6be120241307a, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue May 17 19:15:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999124, encodeId=b3f019991248e, content=<a href='/topic/show?id=215c26381aa' target=_blank style='color:#2F92EE;'>#低钙血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26381, encryptionId=215c26381aa, topicName=低钙血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Thu May 05 09:15:31 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-10 仁者大医
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063500, encodeId=97e3206350068, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 11 07:15:31 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778118, encodeId=b99b1e7811820, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 10 08:15:31 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024130, encodeId=6be120241307a, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue May 17 19:15:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999124, encodeId=b3f019991248e, content=<a href='/topic/show?id=215c26381aa' target=_blank style='color:#2F92EE;'>#低钙血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26381, encryptionId=215c26381aa, topicName=低钙血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Thu May 05 09:15:31 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-17 lujian
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063500, encodeId=97e3206350068, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Aug 11 07:15:31 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778118, encodeId=b99b1e7811820, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue May 10 08:15:31 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024130, encodeId=6be120241307a, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Tue May 17 19:15:31 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999124, encodeId=b3f019991248e, content=<a href='/topic/show?id=215c26381aa' target=_blank style='color:#2F92EE;'>#低钙血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26381, encryptionId=215c26381aa, topicName=低钙血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Thu May 05 09:15:31 CST 2022, time=2022-05-05, status=1, ipAttribution=)]

相关资讯

J Bone Miner Res:几种降压药与PTH

噻嗪类利尿剂(TZ)与更高的骨密度相关,而袢利尿剂(LD)与更低的骨密度和骨折相关。甲状旁腺细胞可表达二氢吡啶敏感的钙通道,可能在甲状旁腺素(PTH)调节中发挥作用。利尿剂和钙通道阻滞剂(CCBs)调节PTH和钙平衡间可能存在一个潜在的影响骨骼结局的机制。研究者假设,使用LD和二氢吡啶类CCBs会增高PTH,而TZ会降低PTH。因此研究者进行了一项横断面研究,纳入了多种族动脉粥样硬化研究中的188

JCEM:PTH是心脏重构的决定性因素之一

PTH与左室重量和左室射血分数的关系 新的证据提示维生素D和PTH在心脏疾病的发展中发挥作用。为了探讨在横断面下,25羟维生素D(25OHD)和PTH浓度是否与磁共振成像(MRI)的心脏结构和功能相关,来自荷兰阿姆斯特丹自由自由大学健康科学系的A J van Ballegooijen教授及其团队进行了一项研究,该研究发现在老年的白种人群,血清25OHD浓度与MRI测量的心脏结构和功能无关,较高的

J Hypertens:血压和甲状旁腺激素对主动脉脉搏波速度具有独立的效应!

动脉硬化程度,通过PWV来评估,随着BP和PTH的增加而独立地增加,但血压仍是动脉硬化的主要驱动因素。

甲状旁腺素的生物学研究与成骨作用

甲状旁腺素对Ⅰ型骨质疏松(绝经后骨质疏松症)、Ⅱ型骨质疏松(老年骨质疏松症)、雌激素缺乏的年轻妇女及糖皮质激素所致的骨质疏松症均有治疗作用。

默沙东口服骨质疏松症药物MK-5442中期试验失败

在一项2期剂量范围研究中,患有骨质疏松症的绝经后妇女使用默沙东的口服钙敏感受体拮抗剂试验药物MK-5442进行治疗,显示骨形成指标增加,但这款药物不能提升骨密度(BMD)。据挪威奥斯陆的医学博士Halse及其同行称,到第6个月时,接受该试验药物治疗的患者其血清前胶原1N端肽(s-P1NP)水平与安慰剂组相比有明显增加。 试验中,随机接受7.5、10或15mg/天药物治疗的妇女与安慰剂相比,s-P

JCEM:PTH治疗可改善甲状旁腺功能减退患者的生活质量

来自甲状旁腺功能减退患者的主诉,经常反映了生活质量(QOL)的下降,然而,描述这些主诉以及甲状旁腺激素(PTH)治疗在改善这些痛苦的潜在作用的数据很少。为了验证PTH(1–84)治疗是否能改善甲状腺旁腺功能减退患者的生活质量,来自美国哥伦比亚大学内科和外科学院的John P Bilezikian博士及其团队进行了一项研究,该研究发现PTH(1–84)治疗甲状旁腺功能减退可改善生理和心理功能。该研究